We aimed to evaluate clinical effects of additional heart rate control by ivabradine on life quality score and 6-minute walking test in patients with previously implanted biventricular cardiac resynchronization therapy defibrillator (CRT-D) with ischemic heart failure under regular treatment.
Methods
Fifteen men and 14 women with a median age of 63 years (range, 48–79 years) were studied. Twenty-one patients were in New York Heart Association class II (8 patients were in class III), CRT-D implanted previously, and with resting heart rates greater than 70 beats per minute with sinus rhythm despite conventional medication. Patients were given 2.5- to 7.5-mg ivabradine orally twice a day, and drug dosage was titrated to decrease the patients’ average heart rate to 70 beats per minute. Before and 3 months after ivabradine treatment, all patients underwent extensive clinical, echocardiographic, and laboratory evaluation.
Results
Ivabradine treatment produced dose-dependent reductions in heart rate at rest and at peak exercise (91.9 ± 6.3 to 71.7 ± 4.8 and 114.4 ± 7.6 to 96.8 ± 4.8; P = 0.001 and P = 0.001, respectively). There were also significant improvements in life quality score (52.4 ± 9.5 to 37.9±7.8; P = 0.001) and 6-minute walking distance (278.7 ± 85.8 to 373.3 ± 94.0; P = 0.001) of patients. All patients with New York Heart Association class III became class II after 3 months of ivabradine treatment.
Conclusion
Heart rate reduction in a short-term period by ivabradine produced significant improvements in exercise capacity and life quality in patients with CRT-D and conventional therapy.
BleuminkGS, KnetschAM, SturkenboomMC, . Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure. The Rotterdam Study. Eur Heart J. 2004; 25: 1614–1619.
2.
DaviesM, HobbsF, DavisR, . Prevalence of left ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study. Lancet. 2001; 358: 439–444.
3.
Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction—pharmacological approaches. J Card Fail. 1999; 5: 357–382.
4.
AHA medical/scientific statement. 1994 revisions to classification of functional capacity and objective assessment of patients with diseases of the heart. Circulation. 1994; 90: 644–645.
5.
Gwadry-SridharFH, FlintoftV, LeeDS, . A systematic review and meta-analysis of studies comparing readmission rates and mortality rates in patients with heart failure. Arch Intern Med. 2004; 164: 2315–2320.
6.
KayaMG, UyarelH, AkpekM, . Prognostic value of uric acid in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Am J Cardiol. 2012; 4: 486–491.
7.
BöhmM, SwedbergK, KomajdaM, . Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet. 2010; 376: 886–894.
8.
FoxK, FordI, StegPG, . Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. Lancet. 2008; 372: 817–821.
9.
HigginsSL, HummelJD, NiaziIK, . Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias. J Am Coll Cardiol. 2003; 42: 1454–1459.
10.
ClelandJG, DaubertJC, ErdmannE, . Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005; 352: 1539–1549.
11.
Rivero-AyerzaM, TheunsDA, Garcia-GarciaHM, . Effects of cardiac resynchronization therapy on overall mortality and mode of death: a meta-analysis of randomized controlled trials. Eur Heart J2006; 27: 2682–2688.
12.
BradleyDJ, BradleyEA, BaughmanKL, . Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. JAMA. 2003; 289: 730–740.
13.
McAlisterFA, EzekowitzJA, WiebeN, . Systematic review: cardiac resynchronization in patients with symptomatic heart failure. Ann Intern Med. 2004; 141: 381–390.
14.
VatankuluMA, GoktekinO, KayaMG, . Effect of long-term resynchronization therapy on left ventricular remodeling in pacemaker patients upgraded to biventricular devices. Am J Cardiol. 2009; 9: 1280–1284.
15.
DicksteinK, VardasPE, AuricchioA, . ESC Committee for Practice Guidelines. 2010 Focused update of ESC guidelines on device therapy in heart failure: an update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Europace. 2010; 12: 1526–1536.
16.
GilesPD, RylancePB, CrothersDC.New results from the Modification of Diet in Renal Disease study: the importance of clinical outcomes in test strategies for early chronic kidney disease. QJM. 2008; 101: 155–158.
17.
McGavinCR, ArtvinliM, NaoeH, . Dyspnoea, disability, and distance walked: comparison of estimates of exercise performance in respiratory disease. Br Med J. 1978; 2: 241–243.
18.
RectorT, KuboS, CohnJ.Patients self-assessment of their congestive heart failure: content, reliability, validity of a new measure, the Minnesota Living with Heart Failure Questionnaire. Heart Fail. 1987; 3: 198–209.
19.
KoDT, HebertPR, CoffeyCS, . Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA. 2002; 288: 351–357.
20.
FogariR, ZoppiA, CorradiL, . Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study. Am J Hypertens. 1998; 11: 1244–1247.
21.
TafreshiMJ, WeinacherAB.Beta-adrenergic-blocking agents in bronchospastic diseases: a therapeutic dilemma. Pharmacotherapy. 1999; 19: 974–978.
22.
Di FrancescoD.Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res. 2006; 53: 399–406.
23.
FrankeJ, SchmahlD, LehrkeS, . Adjuvant use of ivabradine in acute heart failure due to myocarditis. Case Report Med. 2011;2011:203690.
24.
ColinO, GhalehB, HittingerL, . Differential effects of heart rate reduction and beta-blockade on left ventricular relaxation during exercise. Am J Physiol Heart Circ Physiol. 2002; 282: H672–H679.
25.
SimonL, GhalehB, PuybassetL, . Coronary and hemodynamic effects of S16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther. 1995; 275: 659–666.
26.
CeconiC, FreedmanSB, TardifJC, . BEAUTIFUL Echo-BNP Investigators. Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL. Int J Cardiol. 2011; 3: 408–414.
27.
SarulloFM, FazioG, PuccioD, . Impact of “off-label” use of ivabradine on exercise capacity, gas exchange, functional class, quality of life, and neurohormonal modulation in patients with ischemic chronic heart failure. J Cardiovasc Pharmacol Ther. 2010; 4: 349–355.
28.
TardifJC, O'MearaE, KomajdaM, . SHIFT Investigators. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. Eur Heart J. 2011; 32: 2507–2515.
29.
PostF, MünzelT.Ivabradine—a new therapeutic option for cardiogenic shock?Herz. 2009; 34: 224–229.
30.
De FerrariGM, MazzueroA, AgnesinaL, . Favorable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur J Heart Fail. 2008; 10: 550–555.
31.
MulderP, BarbierS, ChagraouiA, . Long-term heart rate reduction induced by the selective If current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation. 2004; 109: 1674–1679.
32.
KanorskiıSG, TregubovVG, PokrovskiıVM. Alternative therapy with ivabradine in patients with functional class III chronic heart failure. Kardiologiia. 2011; 51: 39–44.
